Welcome to our dedicated page for Envista Holdings news (Ticker: NVST), a resource for investors and traders seeking the latest updates and insights on Envista Holdings stock.
Envista Holdings Corporation reports recurring developments as a global dental products company serving dental professionals through consumables, technologies, equipment and services. Its public updates center on quarterly results, core sales trends, adjusted earnings measures, cash flow, share repurchase activity and management presentations at healthcare conferences.
Company news also covers product and brand activity across DEXIS, Kerr, Nobel Biocare and Ormco, including dental implants, orthodontics, digital imaging, restorative and endodontic solutions. Recent product announcements include Kerr Dental's ZenSeal Pro with ZenSave Tips, reflecting Envista's focus on dental workflow, treatment technology and clinician-facing product commercialization.
Envista Holdings Corporation (NYSE: NVST) announced its participation in the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 9:20 AM CT, and the Stifel 2021 Virtual Jaws & Paws Conference on June 2, 2021, at 3:30 PM ET. Investors can access these events through the company's Investor Relations website. Envista, a leader in dental products, supports dental professionals globally with a broad range of solutions aimed to improve patient care and treatment outcomes.
Envista Holdings Corporation (NYSE: NVST) will participate in the Bank of America Healthcare Conference on May 11, 2021, at 11:45 AM ET. Investors can access the event via Envista's Investor Relations website.
As a leading dental products company, Envista offers a comprehensive portfolio that meets about 90% of dentists' clinical needs. The company, which separated from Danaher Corporation in 2019, focuses on continuous improvement and innovation in dental care solutions.
Envista Holdings Corporation (NYSE: NVST) reported a robust Q1 2021 with sales of $709.2 million, a 29.6% increase year-over-year. Core sales rose 29.7%, despite a 3.1% decline from discontinued products. Net income was $71.7 million or $0.41 per diluted share, while adjusted net income reached $95.4 million or $0.54 per diluted share. Adjusted EBITDA surged to $148.0 million compared to $19.4 million in Q1 2020. The CEO expressed optimism about continued growth in the dental market, emphasizing the company's dedication to organic growth and improving operating margins.
Envista Holdings Corporation (NYSE: NVST) has formed a partnership with Curaeos to enhance dental services across the Netherlands, Belgium, Denmark, Germany, and Italy. This collaboration aims to provide innovative dental solutions through Envista's renowned brands such as KaVo and Nobel Biocare, empowering Curaeos' network of clinics to deliver superior patient care. Both companies are committed to improving the patient experience by offering access to training and educational programs through the Curaeos Academy.
Envista Holdings Corporation (NYSE: NVST) will announce its Q1 2021 financial results on May 5, 2021, followed by a conference call at 2:00 PM PT. The call will last approximately an hour and will be accessible through Envista's website. A replay will be available post-presentation. Envista, a prominent player in the dental products sector, offers over 30 brands and addresses about 90% of dentists' needs. The company emphasizes its commitment to innovation and customer focus in delivering quality patient care.
Envista Holdings Corporation (NYSE: NVST) announced a four-year contract extension with Heartland Dental, the largest dental support organization in the U.S. This partnership solidifies Envista's role as a major supplier of dental products such as implants and imaging technology. Since their partnership began in 2016, Heartland Dental has accessed Envista's extensive product portfolio, enhancing care for over 1,800 supported dentists. This extension underscores Envista's commitment to quality and support within the dental industry.
Envista Holdings Corporation (NYSE: NVST) reported robust financial results for Q4 2020, with a net income of $108.4 million, translating to $0.64 per diluted share. Adjusted net income stood at $94.6 million, or $0.56 per diluted share. Notably, adjusted EBITDA grew by 23.1% to $150.8 million, and sales rose by 1.6% year-over-year to $732.3 million. Core sales increased by 3.4%, while operating cash flow also saw a rise of 3.4% to $193.4 million. The company repaid $472 million in bank term debt and aims for enhanced performance in 2021.
Envista Holdings Corporation (NYSE: NVST) will report its fourth quarter 2020 financial results on February 10, 2021, followed by a conference call at 2:00 PM PT. The call will be accessible via phone and webcast on Envista's website. The company, known for its extensive range of dental products, aims to help professionals enhance patient care. Envista partners with leading dental brands to address 90% of dentists' clinical needs, covering diagnostics and treatment options.
Envista Holdings Corporation (NYSE: NVST) will participate in the JP Morgan Healthcare Conference on January 11, 2021, at 4:30 PM ET. Investors can access the event via Envista's Investor Relations website. Envista is a leading global dental products company, offering a comprehensive portfolio that covers approximately 90% of dentists' clinical needs. Since separating from Danaher Corporation in 2019, Envista has established a strong market position through its commitment to innovation and customer-focused solutions. For more information, visit www.envistaco.com.
Envista Holdings Corporation (NYSE: NVST) reported its Q3 2020 financial results, showing a net income of $35.6 million, or $0.22 per share. Adjusted net income was $77.9 million, translating to $0.48 per diluted share. Sales fell by 2.9% year-over-year to $640.5 million, but sequential sales improved by 76.9% from Q2 2020. Adjusted EBITDA rose by 18.6% to $131.9 million. Free cash flow surged 70.3% to $134.9 million. The CEO highlighted significant recovery in the dental market and the impact of strategic initiatives on growth and margin.